株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

嘔吐:パイプライン製品の分析

Emesis (Vomiting) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 246019
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
嘔吐:パイプライン製品の分析 Emesis (Vomiting) - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 36 Pages
概要

吐き気(医療用語では「嘔吐」、一般的には様々な用語で表されます)とは、胃の内容物を口から(場合によっては鼻から)強制的に排出することをいいます。嘔吐は様々な状況下で発生します。具体例として、胃炎などの病気や毒物に対する特定の反応や、(脳腫瘍・頭蓋内圧上昇から、電離放射線への過剰露出まで)様々な疾患の一般的な後遺症などが挙げられます。通常は吐き気が嘔吐の前に生じますが、必ずしも連動しているわけではありません。吐き気・嘔吐を抑制するために、鎮吐薬が必要になるときがあります。また、脱水症状が生じるといった深刻な場合には、静脈への輸液が必要となることもあります。鎮吐薬は通常、乗り物酔いや、オピオイド・化学療法といった治療の副作用などを治療する際に用いられます。

当レポートでは、世界各国での嘔吐治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

嘔吐の概要

治療薬の開発

  • 嘔吐向けパイプライン製品:概要
  • 嘔吐向けパイプライン製品:比較分析

各企業で開発中の嘔吐治療薬

大学/研究機関で研究中の嘔吐治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

嘔吐治療薬:開発中の製品の一覧(企業別)

嘔吐治療薬:研究中の製品の一覧(大学/研究機関別)

嘔吐治療薬の開発に従事している企業

  • Astellas Pharma Inc.
  • Charleston Laboratories, Inc.
  • Sparsha Pharma International Pvt. Ltd.
  • NanoForm Therapeutics Ltd.
  • Epiomed Therapeutics, Inc.

嘔吐:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • CL-108
  • CLH-1-T
  • 5-HT3受容体拮抗薬パッチ
  • FK-886
  • ETI-385
  • TRIM-21を標的とする抗体
  • aprepitant
  • CLBPC
  • CLFTC
  • CLHMC
  • CLOXC
  • CLHDC
  • CLH-5
  • CLH-10

嘔吐治療薬:最新の薬剤プロファイル

嘔吐治療薬:開発が休止状態の製品

嘔吐治療薬:開発が中止された製品

嘔吐関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全4件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7457IDB

Summary

Global Markets Direct's, 'Emesis (Vomiting) - Pipeline Review, H2 2015', provides an overview of the Emesis (Vomiting)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Emesis (Vomiting), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emesis (Vomiting) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Emesis (Vomiting)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Emesis (Vomiting) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Emesis (Vomiting) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Emesis (Vomiting)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Emesis (Vomiting) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Emesis (Vomiting) Overview
  • Therapeutics Development
    • Pipeline Products for Emesis (Vomiting) - Overview
    • Pipeline Products for Emesis (Vomiting) - Comparative Analysis
  • Emesis (Vomiting) - Therapeutics under Development by Companies
  • Emesis (Vomiting) - Therapeutics under Investigation by Universities/Institutes
  • Emesis (Vomiting) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Emesis (Vomiting) - Products under Development by Companies
  • Emesis (Vomiting) - Products under Investigation by Universities/Institutes
  • Emesis (Vomiting) - Companies Involved in Therapeutics Development
    • Daewoong Pharmaceutical Co., Ltd.
    • Epiomed Therapeutics, Inc.
    • InteguRx Therapeutics, LLC
  • Emesis (Vomiting) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DWJ-1308 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETI-385 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • granisetron hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEO-1940 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Emesis (Vomiting) - Dormant Projects
  • Emesis (Vomiting) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Emesis (Vomiting), H2 2015
  • Number of Products under Development for Emesis (Vomiting) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Emesis (Vomiting) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Emesis (Vomiting) - Pipeline by Epiomed Therapeutics, Inc., H2 2015
  • Emesis (Vomiting) - Pipeline by InteguRx Therapeutics, LLC, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Emesis (Vomiting) - Dormant Projects, H2 2015
  • Emesis (Vomiting) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Emesis (Vomiting), H2 2015
  • Number of Products under Development for Emesis (Vomiting) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top